Centocor, Inc. clinical trials

Acquired by Johnson & Johnson, Oct 1999 · source ↗

The registry lists 75 studies whose lead sponsor is Centocor, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 23, 2018.

Studies

Recruiting first, then most recently updated. Showing 50 of 75. List all 75 → · All Johnson & Johnson studies →

• A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate TherapyCompletedNCT00718718Phase 2

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)CompletedNCT01362153Phase 1

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With PsoriasisCompletedNCT00925574Phase 1

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT00786201Phase 2

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary AngioplastyCompletedNCT00269893Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.CompletedNCT00269880Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With AbciximabCompletedNCT00271401Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary AngioplastyCompletedNCT00269906Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type PsoriasisCompletedNCT00320216Phase 2

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study to Test the Design, Functionality, and Ergonomic Features of the AutoinjectorCompletedNCT00643526Early Phase 1

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent AsthmaWithdrawnNCT00675649Phase 2

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy ParticipantsCompletedNCT02074800Phase 1

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• Infliximab Plus Methotrexate for the Treatment of Rheumatoid ArthritisCompletedNCT00269867Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's DiseaseCompletedNCT00269841Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's DiseaseCompletedNCT00269854Phase 2/3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naiveCompletedNCT00264537Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)TerminatedNCT00385827Phase 2

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)CompletedNCT00046228Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate TherapyCompletedNCT00361335Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With SarcoidosisCompletedNCT00955279Phase 2

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study of CNTO 328 in Subjects With Metastatic Renal Cell CarcinomaCompletedNCT00265135Phase 1/2

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's DiseaseCompletedNCT00412321Phase 1

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis PigmentosaTerminatedNCT00458575Phase 1

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study of the Pharmacokinetics of Ustekinumab in Chinese Male SubjectsCompletedNCT01081704Phase 1

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study of the Pharmacokinetics of Golimumab in Chinese Male SubjectsCompletedNCT01288157Phase 1

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate CancerCompletedNCT00401765Phase 1

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid TumorsCompletedNCT00841191Phase 1/2

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT00402181Phase 2

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate TherapyCompletedNCT00264550Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Long-term Safety Study of Infliximab (Remicade)CompletedNCT00261976

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)CompletedNCT00299546Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's DiseaseCompletedNCT00265122Phase 2

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate TherapyCompletedNCT00973479Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes MellitusCompletedNCT00882726Phase 1

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With PsoriasisCompletedNCT01008995Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate TherapyCompletedNCT01248780Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).CompletedNCT00380796

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male SubjectsCompletedNCT01258777Phase 1

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 MelanomaCompletedNCT00246012Phase 1/2

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative ColitisCompletedNCT00336492Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic ArthritisCompletedNCT00265096Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing SpondylitisCompletedNCT00265083Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate CancerCompletedNCT00537381Phase 2

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic ArthritisCompletedNCT00267956Phase 2

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF TherapyCompletedNCT00771667Phase 2

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type PsoriasisCompletedNCT00747344Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing SpondylitisCompletedNCT01248793Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT01266811Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• A Phase 1 Study of CNTO 3157 in Healthy Volunteers and Patients With AsthmaCompletedNCT01195207Phase 1

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson

• An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque PsoriasisCompletedNCT00454584Phase 3

  Sponsor listed in the registry: Centocor, Inc. · First submitted after Centocor, Inc. became part of Johnson & Johnson